MannKind Reports Second Quarter Financial Results

MannKind Reports Second Quarter Financial Results

VALENCIA, Calif.--(BUSINESS WIRE)--Sept. 1, 2004-- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the second quarter and six months ended June 30, 2004.

For the second quarter of 2004, total operating expenses were $18.4 million, compared with $13.2 million in the second quarter of 2003. Research & Development (R&D) expenses increased by $5.0 million to $14.3 million primarily due to the increased expenses associated with expanded clinical trials and related support for the Company's Technosphere® Insulin product. General and administrative (G&A) expenses increased by $0.2 million to $4.1 million. The net loss for the second quarter of 2004 was $18.2 million versus a net loss of $13.1 million in the second quarter of 2003. Net loss per share was $0.91 in the second quarter of 2004 compared with a net loss of $0.79 for the comparable 2003 period. Net loss per share, when calculated on a pro forma basis to give effect to the conversion of preferred stock into common stock upon the closing of MannKind's initial public offering on August 2, 2004, was $0.73 in the second quarter of 2004.

For the first six months of 2004, operating expenses totaled $35.0 million compared with $33.6 million in the first half of 2003. R&D expenses were $27.1 million, up $6.2 million, again related primarily to the expansion of clinical trials of MannKind's Technosphere® Insulin program. G&A expenses were $7.8 million, a decrease of $4.9 million from the first half of 2003, when the Company consolidated its California operations into a single facility. For the first half of 2004, the net loss was $34.7 million, versus a net loss of $33.4 million in the first half of 2003.

Cash, cash equivalents and marketable securities at June 30, 2004 were $41.3 million, compared with $55.9 million at December 31, 2003. Subsequent to June 30, 2004, MannKind completed its initial public offering, resulting in net proceeds of approximately $83.6 million, including $4.0 million in proceeds from the exercise of the underwriter's over-allotment option.

About MannKind Corporation

MannKind focuses on the discovery, development and commercialization of therapeutic products for diseases including diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere® Insulin System, which is currently in late Phase II clinical trials for the treatment of diabetes, consists of a proprietary dry powder Technosphere® formulation of insulin that is inhaled into the deep lung using MannKind's MedTone™ inhaler. Early indications show MannKind's proprietary Technosphere® Insulin System's performance characteristics, convenience and ease of use have the potential to change the way diabetes is treated. For more information on MannKind Corporation and its technology, visit

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to our clinical trials and product candidates. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support our operations and other risks detailed in our filings with the SEC, including our Registration Statement on Form S-1. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

                         MannKind Corporation
                 Consolidated Statements of Operations

(In thousands, except share
and per share amounts)         Three Months Ended    Six Months Ended
                               -------------------  ------------------
                               June 30,  June 30,  June 30,  June 30,
                                   2004      2003      2004      2003
                               --------- --------- --------- ---------

Revenue                              $-        $-        $-        $-
                               --------- --------- --------- ---------

Research & development           14,311     9,321    27,110    20,884
General & administrative          4,071     3,903     7,840    12,710
                               --------- --------- --------- ---------
Total operating expenses         18,382    13,224    34,950    33,594
                               --------- --------- --------- ---------
Loss from operations            (18,382)  (13,224)  (34,950)  (33,594)
Interest income                     123       119       221       204
Other income (expense)               14        17        75       (33)
                               --------- --------- --------- ---------
Loss before provision for
 income taxes                   (18,245)  (13,088)  (34,654)  (33,423)
Income taxes                          -         -         -         -
                               --------- --------- --------- ---------
Net loss                        (18,245)  (13,088)  (34,654)  (33,423)
Deemed dividend related to
 beneficial conversion feature
 of convertible preferred stock       -      (875)     (612)     (875)
Accretion on redeemable
 preferred stock                      4       (63)      (60)     (123)
                               --------- --------- --------- ---------
Net loss applicable to common
 stockholders                  $(18,241) $(14,026) $(35,326) $(34,421)
                               ========= ========= ========= =========
Net loss per share:
Basic and diluted                $(0.91)   $(0.79)   $(1.77)   $(2.01)
                               ========= ========= ========= =========
Basic and diluted - pro forma    $(0.73)             $(1.44)
                               =========           =========
Shares used to compute basic
 and diluted net loss per
Basic and diluted                19,975    17,760    19,975    17,117
                               ========= ========= ========= =========
Basic and diluted - pro forma    24,907              24,562
                               =========           =========

Condensed balance sheet data (in thousands):        6/30/04  12/31/03
                                                   --------- ---------

 Cash, cash equivalents and marketable securities   $41,260   $55,945
 Working capital                                     35,865    49,097
 Total assets                                       110,778   125,876
 Deferred compensation and other liabilities            130       404
 Redeemable convertible preferred stock               5,248     5,188
 Deficit accumulated during the development stage  (401,625) (366,971)
 Total stockholders' equity                          97,352   111,577

CONTACT: MannKind Corporation
Dick Anderson, 661-775-5302
Investor Relations:
Lippert/Heilshorn & Associates
Ina McGuinness or Bruce Voss, 310-691-7100
SOURCE: MannKind Corporation


Copyright Nasdaq. Minimum 15 minutes delayed.

lib top


Learn more about MannKind's offices in the United States

Learn Morearrow

Lib bottom